IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV

@article{Falconer2010IP10PT,
  title={IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV},
  author={Karolin Falconer and Galia Askarieh and Nina Weis and Kristoffer Hellstrand and Annette Alaeus and Martin Lagging},
  journal={Scandinavian Journal of Infectious Diseases},
  year={2010},
  volume={42},
  pages={896 - 901}
}
Abstract The aim of this study was to investigate the utility of baseline plasma interferon-gamma inducible protein-10 (IP-10) levels in human immunodeficiency virus (HIV)–hepatitis C virus (HCV) co-infected patients. Baseline IP-10 was monitored during HCV combination therapy in 21 HIV–HCV co-infected patients (HCV genotype 1 (n = 16), 2 (n = 2), and 3 (n = 3)). Lower baseline IP-10 was significantly associated with a rapid decline in HCV RNA, in particular with the first phase reduction, and… Expand
Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection
TLDR
Baseline IP-10 levels are associated with early viral kinetics but not ultimate treatment outcome in acute HCV infection, given previous data showing that patients with high baseline IP- 10 are unlikely to spontaneously clear acute HCv infection, they should be prioritized for early antiviral therapy. Expand
IP-10 in chronic hepatitis C patients treated with high-dose interferon.
TLDR
In patients treated with high induction dose interferon, IP-10 levels at any time point were not predictive for SVR, suggesting that, in this cohort, for prediction of SVR the added value of IP- 10 to IL28B genotype and early viral kinetics is limited. Expand
Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy
TLDR
Higher and broader cytokine responses to pegIFNα-ribavirin therapy were observed in SVR patients compared to NR, and changes in IL-8, MIP-1β, and MCP-1 serum concentrations may be associated with efficacy of pegIFnα- and ribavirin-based therapies in patients coinfected by HCV and HIV. Expand
Association of interferon-γ-induced protein-10 serum levels with virological responses to PEG-interferon-based therapy in hepatitis C virus genotype 1 or 2 chronically infected Chinese patients
TLDR
This study indicated that higher IP-10 serum levels were associated with HCV genotype 1 CHC Chinese patients and were both predictive of SVR and improved predictive performances of IL28B genotype and RVR for SVR. Expand
Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection
TLDR
High IP‐10 levels at acute HCV detection were associated with failure to spontaneously clear HCV, and patients with acuteHCV and high baseline IP‐ 10 levels, particularly >380 pg/mL, should be considered for early therapeutic intervention, and those with low levels should defer therapy for potential spontaneous clearance. Expand
Immunologic al and Genetic Markers Predicting Treatment Outcome in Hepatitis C Virus Infection
Hepatitis C is a blood-borne infection caused by the hepatitis C virus (HCV). A chronic infection, which develops in most infected subjects, may lead to liver cirrhosis with ensuing liver dysfunctionExpand
Danoprevir Monotherapy Decreases Inflammatory Markers in Patients with Chronic Hepatitis C Virus Infection
TLDR
Results suggest that effective treatment with a direct-acting antiviral agent may reduce hepatic inflammation and that first-phase HCV RNA decline during treatment with an NS3/4A protease inhibitor is more robust in patients with high baseline IP-10 concentrations. Expand
Coinfection with Hepatitis C Virus among HIV-1-Infected Individuals Increases Proinflammatory Cytokines and HIV-1 Disease Severity
TLDR
In this regard, HCV CD4+ T cells also play an important role in providing an adaptive response by activating cytotoxic and humoral responses. Expand
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
TLDR
RibaC pilot study finds ribavirin down-regulates IP-10, and may have an anti-viral effect differently regulated across IL28B genotypes. Expand
Influence of the inflammatory response on treatment of hepatitis C with triple therapy.
TLDR
Similar to patterns observed during double therapy, IL-6,IL-8, and RANTES levels were associated with SVR in TT, indicating the potential role of interferon in immune response to hepatitis C virus. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 21 REFERENCES
IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV–HCV Coinfection
TLDR
An IP-10 cutoff level of 400 pg/ml might serve as a useful predictive marker for anti- HCV therapy in HIV-HCV-coinfected patients because it could discriminate patients with expected NR or HCV relapse after therapy from patients with an SVR before starting antiviral treatment. Expand
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
TLDR
Baseline IP-10 levels are predictive of the response to HCV treatment, and these levels decreased 6 weeks into treatment and remained low in patients with an SVR, but rebounded in patients who had detectable HCV RNA after the completion of treatment. Expand
Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
TLDR
In patients with chronic hepatitis C, low levels of intrahepatic and systemic IP‐10 predict a favorable first‐phase decline of HCV RNA during therapy with pegylated interferon and ribavirin for genotypes ofHCV. Expand
IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection
TLDR
Pretreatment IP‐10 levels predict RVR and SVR in patients infected with HCV genotype 1, even in those with higher BMI and viral load, and may prove helpful in decision‐making regarding pharmaceutical intervention. Expand
Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.
TLDR
The measurement of HCV load as early as 2 days after the start of pegylated interferon and ribavirin is a useful tool for the prediction of treatment outcome in individual patients and should be used in clinical practice. Expand
Interferon γ-Inducible Protein 10: A Predictive Marker of Successful Treatment Response in Hepatitis C Virus/HIV-Coinfected Patients
TLDR
IP-10 may be a biomarker of HCV treatment outcome in difficult-to-treat HCV/HIV-coinfected patients. Expand
HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: Feasibility and results of hepatitis C treatment
TLDR
The overall treatment response rate was surprisingly high (73%) and correlated to early virological response and the feasibility of treating this patient group with pegylated-interferon α-2a and ribavirin was evaluated. Expand
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
TLDR
Findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively. Expand
High Levels of Chronic Immune Activation in the T-Cell Compartments of Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1 and on Highly Active Antiretroviral Therapy Are Reverted by Alpha Interferon and Ribavirin Treatment
TLDR
It is described that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells, despite effective antiretroviral therapy. Expand
First phase hepatitis c viral kinetics in previous nonresponders patients
TLDR
The log effectiveness of interferon was lower in nonresponders compared with treatment naive patients and the difference in antiviral effectiveness in previous nonresponder patients was overcome by higher interferons doses. Expand
...
1
2
3
...